concor cor 2,5 mg apvalkotās tabletes
merck serono, sia, latvia - bisoprolola fumarāts - apvalkotā tablete - 2,5 mg
concor cor 5 mg apvalkotās tabletes
merck serono, sia, latvia - bisoprolola fumarāts - apvalkotā tablete - 5 mg
concor 10 mg apvalkotās tabletes
merck serono, sia, latvia - bisoprolola fumarāts - apvalkotā tablete - 10 mg
concor 5 mg apvalkotās tabletes
merck serono, sia, latvia - bisoprolola fumarāts - apvalkotā tablete - 5 mg
concor am 5 mg/5 mg tabletes
merck serono, sia, latvia - bisoprololi fumaras, amlodipinum - tablete - 5 mg/5 mg
concor am 5 mg/10 mg tabletes
merck serono, sia, latvia - bisoprololi fumaras, amlodipinum - tablete - 5 mg/10 mg
concor am 10 mg/10 mg tabletes
merck serono, sia, latvia - bisoprololi fumaras, amlodipinum - tablete - 10 mg/10 mg
concor am 10 mg/5 mg tabletes
merck serono, sia, latvia - bisoprololi fumaras, amlodipinum - tablete - 10 mg/5 mg
dengvaxia
sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - denges - vakcīnas - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 un 4. izmantot dengvaxia būtu saskaņā ar oficiālās rekomendācijas.
faslodex
astrazeneca ab - fulvestrant - krūts audzējs - endokrīnās terapijas, anti-estrogēnu - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. , pirms vai perimenopausal sievietes, kombinējot ārstēšanu ar palbociclib būtu jāapvieno ar luteinizējošais hormona atbrīvojošo hormonu (lhrh) agonistu.